https://scholars.lib.ntu.edu.tw/handle/123456789/628843
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Hartmaier, Ryan J | en_US |
dc.contributor.author | Markovets, Aleksandra A | en_US |
dc.contributor.author | Ahn, Myung Ju | en_US |
dc.contributor.author | Sequist, Lecia V | en_US |
dc.contributor.author | Han, Ji-Youn | en_US |
dc.contributor.author | Cho, Byoung Chul | en_US |
dc.contributor.author | Yu, Helena A | en_US |
dc.contributor.author | Kim, Sang-We | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.contributor.author | Lee, Jong-Seok | en_US |
dc.contributor.author | Su, Wu-Chou | en_US |
dc.contributor.author | Kowalski, Dariusz M | en_US |
dc.contributor.author | Orlov, Sergey | en_US |
dc.contributor.author | Ren, Song | en_US |
dc.contributor.author | Frewer, Paul | en_US |
dc.contributor.author | Ou, Xiaoling | en_US |
dc.contributor.author | Cross, Darren A E | en_US |
dc.contributor.author | Kurian, Nisha | en_US |
dc.contributor.author | Cantarini, Mireille | en_US |
dc.contributor.author | Jänne, Pasi A | en_US |
dc.date.accessioned | 2023-03-02T01:57:21Z | - |
dc.date.available | 2023-03-02T01:57:21Z | - |
dc.date.issued | 2023-01-09 | - |
dc.identifier.issn | 2159-8274 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/628843 | - |
dc.description.abstract | MET-inhibitor and EGFR tyrosine kinase inhibitor (EGFR-TKI) combination therapy could overcome acquired MET-mediated osimertinib resistance. We present the final phase Ib TATTON (NCT02143466) analysis (Part B, n = 138/Part D, n = 42) assessing oral savolitinib 600 mg/300 mg once daily (q.d.) + osimertinib 80 mg q.d. in patients with MET-amplified, EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) and progression on prior EGFR-TKI. An acceptable safety profile was observed. In Parts B and D, respectively, objective response rates were 33% to 67% and 62%, and median progression-free survival (PFS) was 5.5 to 11.1 months and 9.0 months. Increased antitumor activity may occur with MET copy number ≥10. EGFRm circulating tumor DNA clearance on treatment predicted longer PFS in patients with detectable baseline ctDNA, while acquired resistance mechanisms to osimertinib + savolitinib were mediated by MET, EGFR, or KRAS alterations. | en_US |
dc.language.iso | en | en_US |
dc.publisher | AMER ASSOC CANCER RESEARCH | en_US |
dc.relation.ispartof | Cancer discovery | en_US |
dc.subject | TYROSINE KINASE INHIBITORS; PHASE-II PLATFORM; PATIENT; NSCLC; CRIZOTINIB; VOLITINIB; THERAPY; DISEASE; AZD9291; POTENT | en_US |
dc.title | Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1158/2159-8290.CD-22-0586 | - |
dc.identifier.pmid | 36264123 | - |
dc.identifier.scopus | 2-s2.0-85144879255 | - |
dc.identifier.isi | WOS:000908369500001 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85144879255 | - |
dc.relation.pages | 98 | en_US |
dc.relation.journalvolume | 13 | en_US |
dc.relation.journalissue | 1 | en_US |
dc.relation.pageend | 113 | en_US |
item.fulltext | no fulltext | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。